Clinical Trials

46 enrolled

Small Cell Lung Carcinoma

NCT06172296 2026-04-14

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Phase 3 Recruiting

478 enrolled

CNS

Neuroblastoma, Ganglioneuroblastoma

NCT06623422 2026-04-14

INTerpath-009

Phase 3 Recruiting

680 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06890338 2026-04-14

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Phase 2 Recruiting

140 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT07155174 2026-04-14

SEZanne

Phase 2 Recruiting

180 enrolled

Phase 3 Not yet recruiting

Small Cell Lung Carcinoma

NCT07502300 2026-04-14

A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer

562 enrolled

Phase 2 Not yet recruiting

Small Cell Lung Carcinoma

NCT07527806 2026-04-14

Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

156 enrolled

Breast

Breast Neoplasms

NCT01167712 2026-04-13

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase 3 Active not recruiting

692 enrolled 11 charts

Brenner Tumor, Fallopian Tube Neoplasms

NCT01244789 2026-04-13

Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer

244 enrolled

Endometrial Neoplasms

NCT01366144 2026-04-13

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

94 enrolled

Breast Neoplasms, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Unknown Primary, Ovarian Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Liver Failure, Renal Insufficiency

NCT01386385 2026-04-13

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 1/2 Active not recruiting

53 enrolled 21 charts

Phase NA Active not recruiting

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

NCT02194738 2026-04-13

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

8,300 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02609776 2026-04-13

CHRYSALIS

751 enrolled 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT02627443 2026-04-13

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

35 enrolled 13 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02883062 2026-04-13

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

67 enrolled 16 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03289910 2026-04-13

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

MyeloidOther hematologic neoplasm

25 enrolled 15 charts

Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03323463 2026-04-13

Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma